arrow
M

Maria Saigí

CIBERESP
H指数:14
被引数:934

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer
2023-12-011
PRE
Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C

用免疫疗法治疗的具有KRAS突变的转移性肺癌患者队列的特征: 根据KRAS G12C与non-G12C的差异

2023-10-174
OAAI
MYC activation impairs cell-intrinsic IFNy signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer
2023-04-0111
OAAI
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer
2022-09-0617
OAAI
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma
2021-09-2913
OA
Immune response after vaccination against SARS-COV-2 in lung cancer (LC) patients (p). Prospective study in the Medical Oncology Department at the Catalan Institute of Oncology-Badalona, Spain: COVID-lung vaccine
2021-09-010
OAAI
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

使用真实数据的长期晚期 (iiib-iv) EGFR突变的非小细胞肺癌 (NSCLC) 幸存者的预后模型

2021-08-318
OAAI
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade
2021-07-1430
OAAI
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity
2021-03-11118
OA
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors
2020-02-0133
OAAI